Plné znění - 19/2025 Sb.

Sdělení Ministerstva zahraničních věcí, kterým se mění a doplňují sdělení Ministerstva zahraničních věcí č. 58/2007 Sb. m. s. a č. 46/2008 Sb. m. s.

19/2025 Sb.
 

Sdělení

INFORMACE

19

XXXXXXX

Xxxxxxxxxxxx xxxxxxxxxxxx xxxx,

xxxxxx xx mění x xxxxxxxx xxxxxxx Xxxxxxxxxxxx xxxxxxxxxxxx xxxx č. 58/2007 Sb. m. s. x č. 46/2008 Sb. m. s.
&xxxx;

Xxxxxxxxxxxx zahraničních xxxx xxxxxxx, xx xxx 1. xxxxx 2023 xxxx xxxxxxxxx xxxxxxxxxx UNESCO oznámeno xxxxxxxxx xxxxxx xxxxx Xxxxxxx X - Xxxxxx zakázaných látek x metod xxxxxxx xxx xxx 2024 - Mezinárodní standard Xxxxxxxxxxx úmluvy xxxxx xxxxxxx ve xxxxxx.

X xxxxx xxxxxx Přílohy X xxxxxxxx souhlas Xxxxxxxxx Xxxxx xxxxxxxxx x xxxxxxxxx republiky xxxxxxxx xxxxxxx x xxxxxxx xxxx Xxxxxxx X Xxxxxx xxxxxxxxxx.

Xxxx xxxxx Přílohy I xxxxxxxxx v platnost x souladu x článkem 34 xxxx. 3 Xxxxxx dne 1. xxxxx 2024, pro Xxxxxx xxxxxxxxx xxxxxxxxx x xxxxxxxx xxx 18. xxxxxx 2024 x xxxxxxxxx Xxxxxxx X xxx xxx 2023, platnou od 1. xxxxx 2023, xxxxx xxxxxxxxx x xxxxxxxx xxx Xxxxxx xxxxxxxxx xxx 22. xxxxxx 2023 x xxxx xxxxxxxxx xxx č. 32/2023 Sb. m. s.

Xxxxxxxx xxxxx Xxxxxxx X xxx xxx 2024 a xxxx xxxxxxx do českého xxxxxx xx xxxxxxxxx xxxxxxxx.
&xxxx;

Xxxxxxx:

x z. XXXx. Xxxxxx, Xx.X., LL.M., x. x.

xxxxxx xxxxxxx xxxxx xxxxxx a xxxxxxxxxx
&xxxx;

Xxxxxxx x. 1

Xxxxxxx xxxxxxxxxxx smlouvy xx xxxxxxx xxxxxx

Xxxx

Xxxxxx xxxxxxxxxx xxxxx x xxxxx xxxxxxx je xxxxxxx Xxxxxxxxxxx xxxxxxxx x xxxxx Xxxxxxxxx xxxxxxxxxxxxxxx xxxxxxxx.

Xxxxxx je xxxxxxxxxx xxxxxxxxxxxx po rozsáhlém xxxxxxxxxxxx procesu xxxxxxxxxxxxxxxx Xxxxxxxx xxxxxxxxxxxxxx xxxxxxxxx (XXXX). Seznam xx xxxxxx od 1. xxxxx 2024.

Xxxxxxxxx xxxx Xxxxxxx xxxxxxxxxx xxxxx x metod xxxx xxxxxxxxx XXXX x xxxx publikován x xxxxxxxxxx x xxxxxxxxxxxxx. X xxxxxxx xxxxxxxxxxx xxxxxxxxxxxxx mezi xxxxxxxxx x xxxxxxxxxxxx xxxxxx xxxxxxxxx znění v xxxxxxxxxx.

Xxxx xxxx xxxxxxx xxxxxxx pojmy používané x tomto Xxxxxxx xxxxxxxxxx xxxxx x xxxxx.

Xxxxxxxx Při xxxxxxx

Xxxxx XXXX pro xxxx xxxxx xxxxxxxxxxx jiné xxxxxx, xx xxxxxx Xxx xxxxxxx v xxxxxx xxxxxxx xxxxxxxxxxx xxxxx xxxx půlnocí (xx 23:59 xxxxx) x xxx xxxxxxxxxxxxx Xxxxxxx, které se xx Sportovec xxxxxxxxx, xx xx xxxxx Xxxxxxx x procesu xxxxxx Xxxxxx.

Xxxxxxxx xxxxx

Xx xxxxxxx, xx daná xxxxx xxxx metoda xx xxxxxxxx Xxx xxxxxxx x Mimo xxxxxx, xxx je xxxxxxxxxx v Xxxxxx.

Xxxxxxxxxx x Xxxxxxxxxxxx

Xxxxx xxxxxx 4.2.2 Světového antidopingového Xxxxxx „xxx účely xxxxxxxx xxxxxx 10 xxxxx xxxxxxx Zakázané xxxxx Xxxxxxxxxxxx xxxxxxx, x xxxxxxxx xxxx xxxxxxxxxx x Seznamu xxxxxxxxxx látek x xxxxx xxxxxxx. Žádná Xxxxxxxx xxxxxx xxxxxx Xxxxxxxxxxx xxxxxxx, xxxxx xxxx x Xxxxxxx xxxxxxxxx xxxxxxxx xxxx Xxxxxxxxxx xxxxxx.“ Podle xxxxxxxxx x xxxxxx „Xxxxxxxxxx látky a Xxxxxxxxxx xxxxxx xxxxxxx x článku 4.2.2 xx neměly xxx xxxxxx xxxxxxxx považovány xx xxxx xxxxxxxx xxxx xxxx xxxxxxxxxx xxx xxxx xxxxxxxxx xxxxx xxxx xxxxxx. Xxx spíše o xxxxx x metody, xxxxx Xxxxxxxxx xxxxxxxxxxxxx xxxx xxxx xxxxxx x xxxxxx účelu xxx ke xxxxxxxx xxxxxxxxxxx výkonu.“

Návykové xxxxx

Xxxxx xxxxxx 4.2.3 Kodexu xxxx Návykové látky xxxxxxxxxx xxxx xxxxx, xxxxx jsou xxxx xxxxxx označeny x xxxxxx jejich častého xxxxxxxxxx ve xxxxxxxxxxx xxxx xxxxx xxxxxx. Xxxx Xxxxxxxx látky xxxx xxxxxxxxxx tyto xxxxx: kokain, xxxxxxxxx (xxxxxx), xxxxxxxxxxxxxxxxxxxxxxxxx (XXXX/„xxxxxx“), xxxxxxxxxxxxxxxxxxx (XXX).

X0 XXXXXXXXXXX XXXXX

XXXXXXXX STÁLE (PŘI XXXXXXX X MIMO XXXXXX)

Xxxxxxx xxxxxxxx xxxxx x xxxx xxxxx xxxx Specifické látky.

Jakákoliv xxxxxxxxxxxxxx látka, xx xxxxxx se nevztahuje xxxxx x následujících xxxxxx Xxxxxxx x xxxxx xxxx v xxxxxxxx době schválena xxxxxx xxxxxxx zdravotnickým xxxxxxxxxx orgánem xxx xxxxxxx použití x xxxx (např. xxxxxx x xxxxxxxxxxxxx xxxx xxxxxxxxx xxxxxx xxxx xxxxxxx vývoj xxx xxxxxxx, xxxxxxxxxx drogy, xxxxx schválené xxxxx xxx xxxxxxxxxxx xxxxxxx), xx zakázána xxxxx.

Xxxx xxxxx xxxxxxxx mnoho xxxxxxx látek, xxxx xxxx XXX-157, 2,4-xxxxxxxxxxxx (XXX) x aktivátory xxxxxxxxx (xxxx. Xxxxxxxxxxx x Tirasemtiv).

S1 XXXXXXXXXX XXXXX

XXXXXXXX XXXXX (PŘI XXXXXXX I MIMO XXXXXX)

Xxxxxxx zakázané xxxxx x této xxxxx xxxx Xxxxxxxxxxxx xxxxx.

Xxxxxxxxxx xxxxx jsou xxxxxxxx.

X1.1. XXXXXXXXXX XXXXXXXXXX XXXXXXXX (XXX)

Xxx xxxxxxxxx xxxxxx, xxxx jiné včetně:

•	1-androstenediol (5ɑ-xxxxxxx-1-xx-3ß, 17ß-xxxx)	&xxxx;&xxxx;&xxxx;&xxxx;&xxxx;&xxxx;&xxxx;&xxxx;&xxxx;&xxxx;&xxxx;	&xxxx;•&xxxx;	xxxxxxxxxx
•	1-xxxxxxxxxxxxxx (5ɑ-xxxxxxx-1-xx-3,17-xxxx)		&xxxx;•	xxxxxxxxx (17ɑ-xxxxxx [1,2,5]xxxxxxxxxx[3’,4’:2,3]-5ɑ-xxxxxxxxx-17ß-xx)
•	1-xxxxxxxxxxx (3ɑ-xxxxxxx-5x-xxxxxxx-1-xx-17-xx)		&xxxx;•	xxxxxxxxx
•	1-xxxxxxxxxxxxxx (3ß-xxxxxxx-5ɑ-xxxxxxx-1-xx-17-xx)		&xxxx;•	xxxxxxxxxx
•	1-xxxxxxxxxxx (17ß-xxxxxxx-5ɑ-xxxxxxx-1-xx-3-xx)		&xxxx;•	xxxxxxxxxx
•	4-xxxxxxxxxxxxxx (xxxxxxx-4-xx-3ß, 17ß-xxxx)		&xxxx;•	xxxxxxxxxxx (17ß-xxxxxxx-17ɑ-xxxxxxxxxxxxxx-1,4-xxxx-3-xx)
•	4-xxxxxxxxxxxxxxxxxx(4,17ß-xxxxxxxxxxxxxxxx-4-xx-3-xx)		&xxxx;•	xxxxxxxxx
•	5-xxxxxxxxxxxxxx (androst-5-en-3,17-dion)		•	metandriol
•	7ɑ-hydroxy-DHEA		•	metasteron (17β-xxxxxxx-2α,17α-xxxxxxx-5α-xxxxxxxxx-3-xx)
•	7ß-xxxxxxx-XXXX		&xxxx;•	xxxxx-1-xxxxxxxxxxx (17ß-xxxxxxx-17ɑ-xxxxx-5ɑ-xxxxxxx-1-xx-3-xx)
•	7-xxxx-XXXX		&xxxx;•	xxxxxxxxxxxxxx
•	11ß-xxxxx-19-xxxxxxxxxxxxxx		&xxxx;•	xxxxxxxxxxxxx (17β-hydroxy-17α-metylestra-4,9-dien-3-on)
•	17ɑ-methylepithiostanol (xxxxxxx)		&xxxx;•	xxxxxxxxxxxxxxxxxxx (17ß-xxxxxxx-17ɑ-xxxxxxxxx-4-xx-3-xx)
•	19-xxxxxxxxxxxxxxxxx (xxxx-4-xx-3,17-xxxx)		&xxxx;•	xxxxxxxxxxxxxxxx
•	19-xxxxxxxxxxxxxxxxx (xxxx-4-xx-3,17-xxxx)		&xxxx;•	xxxxxxxxxx (xxxxxxxxxxxxxx, 17ß-xxxxxxx-17ɑ-xxxxxxxxxxx-4,9,11-xxxxx-3-xx)
•	Xxxxxxx-4-xx-3,11,17-xxxxx(11-xxxxxxxxxxxxxxxxxx, xxxxxxxxxxxx)		&xxxx;•	xxxxxxxxx
•	xxxxxxxxxxxxx (5ɑ-xxxxxxxxxxxxxxxxxx, 17ß-xxxxxxx-5ɑ-xxxxxxxxx-3-xx)		&xxxx;•	xxxxxxxxx (19-xxxxxxxxxxxxxx)
•	xxxxxxxxxxxxxx (xxxxxxx-5-xx-3ß,17ß-xxxx)		&xxxx;•	xxxxxxxxxx
•	xxxxxxxxxxxxxx (androst-4-en-3,17-dion)		•	norklostebol (4-xxxxxx-17β-xx-xxxx-4-xx-3-xx)
•	xxxxxxxxxx		&xxxx;•	xxxxxxxxxxxxx
•	xxxxxxxx		&xxxx;•	xxxxxxxx
•	xxxxxxx (xxxxxxxx-1,4-xxxx-3,17-xxxx)		&xxxx;•	xxxxxxxxxx
•	xxxxxxxxxx		&xxxx;•	xxxxxxxxxxx
•	xxxxxxxxx		&xxxx;•	xxxxxxxxxx
•	xxxxxxx ([1,2]xxxxxxx[4’,5’:2,3]xxxxxx-4-xx- 20-xx-17ɑ-xx)		&xxxx;•	xxxxxxxxx (xxxxxxxxxxxxxxxxxxxxx, DHEA, 3β-xxxxxxxxxxxxxx-5-xx-17-xx)
•	xxxxxxxxxxxxxxxxxxxxxxxxxxxx (4-chloro- 17ß-xxxxxxx-17ɑ-xxxxxxxxxxxxx-1,4-xxxx-3-xx)		&xxxx;•	xxxxxxxxxxx (17β-[(xxxxxxxxxxxxxxx-2-xx)xxx]-1’X-xxxxxxxx[3,4:2,3]-5α-xxxxxxxxx)
•	xxxxxxxxxxxxxxxxxxxxxx (17ɑ-xxxxxx-5ɑ-xxxxxxx-2-xx-17ß-xx x 17ɑ-xxxxx-5ɑ- xxxxxxx-3-xx-17ß- xx)		&xxxx;•	xxxxxxxxx
•	xxxxxxxxxxxxx (7ɑ,11ß-xxxxxxx-19-xxxxxxxxxxxxxx)		&xxxx;•	xxxxxxxxxx
•	xxxxxxxxxxx		&xxxx;•	xxxxxxxxx
•	xxxxxxxxxxxxxx (3β-hydroxy-5α-androstan-17-on)		•	testosteron
•	epi-dihydrotestosteron (17β-xxxxxxx-5β-xxxxxxxxx-3-xx)		&xxxx;•	xxxxxxxxxxxxxxxxxxx (17-xxxxxxx-18x-xxxx-19-xxx-17ɑ-xxxxxx-4,9,11-xxxxx-3-xx)
•	xxxxxxxxxxxxxx		&xxxx;•	xxxxxxx
•	xxxxxxxxxxxx (19-xxxxxxxxx-4-xx-17α-xx)		&xxxx;•	xxxxxxxxx (17β-hydroxyestr-4,9,11-trien-3-on)
•	fluoxymesteron		•	trestolon (7ɑ-xxxxx-19-xxxxxxxxxxxxxx, MENT)

a další xxxxx x xxxxxxxx xxxxxxxxx xxxxxxxxxx nebo xxxxxxxxx xxxxxxxxxxxx účinky.

S1.2. XXXXXXX XXXXXXXXXX XXXXX

Xxxx xxxx xxxxxx:

Xxxxxxxxxxx, osilodrostat, xxxxxxxxxx, selektivní xxxxxxxxxx xxxxxxxxxxxxx xxxxxxxxx [XXXX, xxxx. andarin, xxxxxxxxx (xxxxxxx), XXX-4033 (xxxxxxxxx), XXX140, X-23 x XX-11], zeranol a xxxxxxxxxx.

X2 PEPTIDOVÉ XXXXXXX, XXXXXXX XXXXXXX, PŘÍBUZNÉ XXXXX A XXXXXXXX

XXXXXXXX XXXXX (PŘI XXXXXXX X XXXX XXXXXX)

Xxxxxxx xxxxxxxx xxxxx x xxxx xxxxx xxxx Xxxxxxxxxxxx xxxxx.

Xxxxxxxxxxx látky x xxxxx látky x podobnou xxxxxxxxx xxxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxxx účinky jsou xxxxxxxx.

X2.1. XXXXXXXXXXXXX (XXX) X XXXXX XXXXXXXXXXX XXXXXXXXXXX

Xxxx jiné včetně:

S2.1.1 Xxxxxxxx xxxxxxxxxxxxxxxxx xxxxxxxxx, xxxx. darbepoetiny (xXXX); xxxxxxxxxxxxx (XXX); xxxxxxxxxx xxxxxxxx xx EPO, [xxxx. EPO-Fc, metoxypolyetylenglykol-epoetin xxxx (XXXX)]; XXX- xxxxxxxxx xxxxxxxxxx x xxxxxx xxxxxxxxxx, xxxx. XXXX-530, peginesatid.

S2.1.2 Xxxxxxxxx xxxxxxxxxx xxxxxxx xxxxxxxxxxxxxx xxxxxxx (XXX), xxxx. xxxxxx; xxxxxxxxxxx (GSK1278863); XXX2; molidustat (XXX 85-3934); xxxxxxxxxx (XX-4592); xxxxxxxxxx (XXX-6548); xxxxx.

X2.1.3 Xxxxxxxxxx XXXX, xxxx. X-11706.

X2.1.4 Xxxxxxxxxx xxxxxxxxxxx xxxxxxxxxxxxxxxx xxxxxxxxx xxxxxxx xxxx (XXX-β), xxxx. xxxxxxxxxxxx; xxxxxxxxxxx.

X2.1.5 Agonisté xxxxxxxxx xxxxxxxxx receptoru, xxxx. xxxxxx EPO; xxxxxxxxxxxxx EPO (CEPO).

S2.2. XXXXXXXXX XXXXXXX A XXXXXX XXXXXXXXXX FAKTORY

S2.2.1 Xxxxxxx xxxxxxxxxxx xxxxxxxxxxx x xxxx, xxxx xxxx včetně:

• xxxxxxxx xxxxxxxxxxxx (CG),

• luteinizační xxxxxx (XX),

• xxxxxx xxxxxxxxxx xxxxxxxxxxxx (XxXX, xxxxxxxxxxx) a xxxx xxxxxxxxxxx analogy (xxxx. xxxxxxxxx, deslorelin, goserelin, xxxxxxxxx, xxxxxxxxxxx, nafarelin x xxxxxxxxxxx),

&xxxx;• xxxxxxxxxx x jeho xxxxxxxxxxx xxxxxxx.

X2.2.2 Xxxxxxxxxxxxxx x xxxxxx xxxxxxxxxx xxxxxxx, xxxx. kortikorelin a xxxxxxxxxxxxx.

X2.2.3 Xxxxxxx xxxxxx (XX), xxxx xxxxxxx x xxxxxxxxx, mimo xxxx včetně:

• xxxxxxx xxxxxxxxx xxxxxxx, např. xxxxxxxxxxxxxxxxx, somapacitan x xxxxxxxxxx,

• xxxxxxxxx růstového xxxxxxx, xxxx. AOD-9604 x xXX 176–191.

X2.2.4 Xxxxxxx xxxxxxxxxx xxxxxxx xxxxxx, xxxx xxxx xxxxxx:

• hormon xxxxxxxxxx xxxxxxx hormon (XXXX) x xxxx xxxxxxx, xxxx. XXX-1293, CJC-1295, xxxxxxxxxx x tesamorelin,

• xxxxxxxxxxx xxxxxxxxx xxxxxxx (XXX) a xxxxxx xxxxxxxx [např. xxxxxxxxxx, xxxxxxxxxxxx, ibutamoren (MK-677), xxxxxxxxxx, xxxxxxxxxxx (xxxxxxx), xxxxxxxxxxx x xxxxxxxxxxx],

• xxxxxxx xxxxxxxxxx GH (XXXX) [xxxx. xxxxxxxxxxxx, xxxxxxxxxx (xxxxxxxxx), XXXX-1, XXXX-2 (pralmorelin), GHRP-3, XXXX-4, GHRP-5 x XXXX-6].

X2.3. RŮSTOVÉ FAKTORY X XXXXXXXXXX XXXXXXXXX XXXXXXX

Xxxx xxxx xxxxxx:

• xxxxxxxxxxxxx růstové faktory (XXX)

• xxxxxxxxxxxx xxxxxxx xxxxxx (HGF)

• xxxxxxx xxxxxx 1 xxxxxxx xxxxxxxx (XXX-1, xxxxxxxxxx) x jeho analogy

• xxxxxxxxxx xxxxxxx faktory (XXX)

• xxxxxxx xxxxxx xxxxxxxx x xxxxxxxx xxxxxxxx (XXXX)

• thymosin-β4 x jeho xxxxxxxx, xxxx. XX-500

• xxxxxxxxxx-xxxxxxxxxxxx xxxxxxx faktor (XXXX)

x xxxxx xxxxxxx xxxxxxx xxxx xxxxxxxxxx růstových xxxxxxx xxxxxxxxxxx xxxxxxx/xxxxxxxxx xxxxxxxx xx svalech, xxxxxxxx xxxx xxxxxx, xxxxxxxxxxxxx, využití xxxxxxx, xxxxxxxxxxxxx xxxxxxxx xxxx xxxxxxxxxxx typy svalových xxxxxx.

X3 XXXX-2 XXXXXXXX

XXXXXXXX XXXXX (PŘI SOUTĚŽI X XXXX SOUTĚŽ)

Všechny xxxxxxxx xxxxx x xxxx xxxxx jsou Xxxxxxxxxx xxxxx.

Xxxxxxx xxxxxxxxxx x xxxxxxxxxxxx xxxx-2 xxxxxxxx xxxxxx všech xxxxxxxxx xxxxxxx jsou xxxxxxxx.

Xxxx jiné včetně:

•	arformoterol		•	indakaterol		•	reproterol		•	tretoquinol (xxxxxxxxxxxxx)
•	xxxxxxxxx		•	xxxxxxxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxxx
•	xxxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxx
•	xxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxx

XXXXXXX

• Inhalační xxxxxxxxxx: xxxxxxxxx 1600 xxxxxxxxxx xx 24 xxxxx x xxxxxxxxxx dávkách, xxxxxxxxxxxxxxxx 600 xxxxxxxxxx xxxxx 8 xxxxx xx xxxxxxxxx xxxxx;

• xxxxxxxxx formoterol: xxxxxxxxx xxxxxx xxxxx 54 xxxxxxxxxx xx 24 xxxxx;

• inhalační xxxxxxxxxx: xxxxxxxxx 200 xxxxxxxxxx xx 24 hodin;

• xxxxxxxxx vilanterol: xxxxxxxxx 25 xxxxxxxxxx za 24 xxxxx.

XXXXXXXX

Xxxxxxxxxx xxxxxxxxxxx x xxxx v xxxxxxxx xxxxxx xxx 1000 xx/xx nebo xxxxxxxxxxx x množství xxxxxx než 40 xx/xx xxxxxxxxxx terapeutickému xxxxxxx xxxxx a xxxx xxxxxxxxxx za Xxxxxxxxx xxxxxxxxxxx nález (XXX), pokud Xxxxxxxxx xxxxxxxxx kontrolovanou xxxxxxxxxxxxxxxxx xxxxxx, xx abnormální xxxxxxxx xxx xxxxxxxxx xxxxxxxxxxxx dávky (xxxxxxxxx) xx xx xxxx xxxxxxx maximální xxxxx.

X4 XXXXXXXXX A METABOLICKÉ XXXXXXXXXX

XXXXXXXX STÁLE (PŘI XXXXXXX X XXXX XXXXXX)

Xxxxxxxx látky xx xxxxxxx X4.1 x X4.2 xxxx Xxxxxxxxxx xxxxx.

Xxxxx xxxxxxxx xx xxxx X4.3 x X4.4 xxxx Xxxxxxxxxxxx xxxxx.

Xxxxxxxxxxx xxxxxxxxx x xxxxxxxxxxx xxxxxxxxxx xxxx xxxxxxxx.

X4.1. XXXXXXXXXX XXXXXXXX

Xxxx xxxx xxxxxx:

•	2-xxxxxxxxxxx (5ɑ-androst-2-en-17-ol)		•	androsta-1,4,6-trien-3,17-dion (xxxxxxxxxxxxxxxxx)
•	2-xxxxxxxxxxx (5ɑ-xxxxxxx-2-xx-17-xx)		•	xxxxxxxx-3,5-xxxx-7,17-xxxx (arimistan)
•	3-androstenol (5ɑ-xxxxxxx-3-xx-17-xx)		•	xxxxxxxxx
•	3-xxxxxxxxxxx (5ɑ-androst-3-en-17-on)		•	formestan
•	4-androsten-3,6,17 xxxxx (6-xxx)		•	xxxxxxxx
•	xxxxxxxxxxxxxxx		•	xxxxxxxxxxx
•	xxxxxxxxxx

X4.2. XXXXXXXXXXXXXX XXXXX [XXXXXXXXXXXXX X XXXXXXXXXX XXXXXXXXXX XXXXXXXXXXXXX RECEPTORŮ (XXXXX)]

Xxxx jiné xxxxxx:

•	xxxxxxxxxxxx		•	xxxxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxxx (xxxxxxxxxxxxx)
•	xxxxxxxxx		•	xxxxxxxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxxx
•	xxxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxx
•	xxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxx

X4.3. LÁTKY ZABRAŇUJÍCÍ XXXXXXXX XXXXXXXXX XXXXXXXX XXX

Xxxx xxxx xxxxxx:

•	xxxxxxxxxx xxxxxxxxxxxxxx aktivin X		•	xxxxxxxxxx xxxxxxxxxx, xxxx.:
•	xxxxxxxxxx xxxxxxxxx xxxxxxxx XXX, xxxx.:			- xxxxx xxxxxxxxx nebo xxxxxx expresi xxxxxxxxxx
	- xxxxxxx xxxxxxxxx xxxxxxxx (xxxx. XXX-031)			- xxxxxxxx xxxxxx xxxxxxxxx (xxxx. xxxxxxxxxxx, propeptid myostatinu)
•	protilátky xxxxx receptoru aktivinu XXX (xxxx. xxxxxxxxxx)			- xxxxxxxxxx xxxxxxxxxxxxxx xxxxxxxxx xxxx xxxxxxxxxx (xxxx. xxxxxxxxxxx, xxxxxxx zumab, xxxxxxxxxxxxx, xxxxxxxxxx)

X4.4. METABOLICKÉ XXXXXXXXXX

X4.4.1 xxxxxxxxxx XXX-xxxxxxxxxx xxxxxxxxxxxxx (XXXX), xxxx. XXXXX, agonisté xxxxxxxxxxxxxx xxxxxxxxxxx xxxxxxxxxxxx xxxxxxxxx xxxxx (XXXXδ), např. 2-(2-xxxxx-4-((4-xxxxx-2-(4- (xxxxxxxxxxxxx)xxxxx)xxxxxxx-5-xx)xxxxxxxxx)xxxxxx) xxxxxxxx xxxxxx (GW1516, XX501516) x xxxxxxxx Xxx-xxxɑ , xxxx. SR9009, XX9011

X4.4.2 xxxxxxxx a xxxxxxxx insulinů

S4.4.3 xxxxxxxxx

X4.4.4 xxxxxxxxxxxx

X5 XXXXXXXXX A XXXXXXXXX XXXXX

XXXXXXXX STÁLE (XXX XXXXXXX X XXXX XXXXXX)

Xxxxxxx xxxxxxxx xxxxx v této xxxxx xxxx Xxxxxxxxxx xxxxx.

Xxxxxxx xxxxxxxxx x xxxxxxxxx xxxxx, xxxxxx xxxxx xxxxxxxxx xxxxxxx, xxxx. x- x x-, jsou zakázány.

Mimo xxxx xxxxxx:

•&xxxx; Xxxxxxxxx, xxxx xxxx.:

xxxxxxxxxxxx; xxxxxxxx; xxxxxxxxx; xxxxxxxx; chlortalidon; xxxxxxxx xxxxxxxxxx; furosemid; xxxxxxxxx; metolazon; spironolakton; xxxxxxxx, xxxx. bendroflumethiazid, xxxxxxxxxxxxx a xxxxxxxxxxxxxxxxxx; xxxxxxxxx; xxxxxxxxxx;

• Xxxxxxx, xxxx. xxxxxxxxxx, xxxxxxxxxx, xxxxxxxxx;

• Xxxxxxxxxxx expandéry xxxxxxxx xxxxxxxxxxxx, xxxx.:

xxxxxxx, xxxxxxx, hydroxyetyl xxxxx, xxxxxxxx;

• Desmopresin;

• Probenecid;

a xxxxx látky x xxxxxxxx chemickou xxxxxxxxxx xxxx podobnými biologickými xxxxxx.

XXXXXXX

• xxxxxxxxxxx; xxxxxxxx; x lokální oftalmologické xxxxxxxx xxxxxxxxxx xxxxxxxxxxxxxx (xxxx. xxxxxxxxxx, brinzolamid);

• xxxxxxx podání xxxxxxxxxxx x xxxxx xxxxxxxxx.

XXXXXXXX

Xxxxx xxxxxxxxxxx xxxxxxxx látky xx stanoveným prahovým xxxxxxx: u xxxxxxxxxxx, xxxxxxxxxxx, katinu, xxxxxxxx, xxxxxxxxxxxxx a pseudoefedrinu xx Xxxxxx Xxxxxxxxx xxxxxxxx xxxx případně Xxx Xxxxxxx xx xxxxxxx x diuretikem xxxx xxxxx xxxxxxxxx xxxxxx (xxxxx xxxxxxxxx xxxxxx podání xxxxxxxxxx xxxxxxxxxxxxxx nebo lokálního xxxxxx xxxxxxxxxxx v xxxxxxxx xxxxxxxxx), xxxx xxxxxxxxx xx Pozitivní xxxxxxxxxxx nález (AAF), xxxxx Sportovec nemá xxxxxxxxxx Xxxxxxxxxxxxx xxxxxxx (XX) xx xxxx xxxxx xxxxx x xx, která xxx xxxx xxxxxxx xx xxxxxxxxxx xxxx xxxxx xxxxxxxxx xxxxx.

XXXXXXXX XXXXXX

XXXXXXXX XXXXX (PŘI XXXXXXX X XXXX XXXXXX)

Xxxxxxx xxxxxxxx metody x xxxx xxxxx jsou Xxxxxxxxxxxx x xxxxxxxx xxxxx x X2.2, xxx xxxx Xxxxxxxxxx xxxxxx.

X1. XXXXXXXXXX X XXXX A KREVNÍMI XXXXXXXXXXXX

Xxxxxxxx xx xxxxxxxxxxx:

X1.1. Xxxxxx xxxx xxxxxxxx xxxxxxxx xxxxxxxxxxx xxxxxxxx xxxxxxxxx, xxxxxxxxx (xxxxxxxxx) xxxx heterologní xxxx xxxx xxxxxxxx x xxxxxxxxx xxxxxxx jakéhokoliv xxxxxx xx xxxxxxxxx xxxxxxx s xxxxxxxx xxxxxxxx xxxxxx xxxx xxxxxx složek Xxxxxxxxx xxxxxxxxxxxxxxx plazmaferézy xxxxxxxxx x registrovaném xxxxxxxxx xxxxxx.

X1.2. Xxxxx zvyšování xxxxxx, přenosu xxxx xxxxxxx xxxxxxx.

Xxxx jiné xxxxxx:

Xxxxxxxxxxxxxxxxxxx; xxxxxxxxxxx (XXX13); xxxxxxxxx a xxxxxxxxxxxx xxxxxxxxxxxxx xxxxxxxx, xxxx. xxxxxx náhražky xx xxxx hemoglobinu x xxxxxxxxxxxxxxxx xxxxxxxxxxxxx xxxxxxxx, x xxxxxxxx xxxxxxxxxxx xxxxxxx xxxxxxxx.

X1.3. Jakákoliv xxxxx xxxxxxxxxxxxxxx xxxxxxxxxx x xxxx nebo x krevními xxxxxxxxxxxx xxxxxxxxxxx xxxx chemickými xxxxxxx.

X2. CHEMICKÁ X XXXXXXXXX MANIPULACE

Zakázané xx xxxxxxxxxxx:

X2.1. Xxxxxxxxx xxxx Xxxxx o xxxxxx xx účelem porušit xxxxxxxxx x xxxxxxxx Xxxxxx odebraných xxx Xxxxxxxxx xxxxxxxx.

Xxxx jiné xxxxxx:

Xxxxxx a/nebo xxxxxx Xxxxxx, xxxx. xxxxxxxx xxxxxxx xx Xxxxxx.

X2.2. Xxxxxxxxxx infuze x/xxxx xxxxxxx více xxx xxxxxx 100 xx xx 12 xxxxx xxxxx infuzí legitimně xxxxxxxxx x xxxxxxx xxxxxxxxxxxx ošetření, chirurgických xxxxxxx xxxx klinických xxxxxxxxxxxxxx vyšetření.

M3. XXXXXX X XXXXXXX XXXXXX

X xxxxxx xxxxxxxxxxxxxxx xxxxxxx xxxxxxxxxxx výkonu xx xxxxxxxx xxxxxxxxxxx:

X3.1. Použití xxxxxxxxxx xxxxxxx xxxx xxxxxx analogů, xxxxx xxxxx xxxxxx xxxxxxxx xxxxxx a/nebo xxxxxxx xxxx xxxxxxxxxx xxxxxxxxxxx. Xx mimo xxxx xxxxxxxx technologie úprav xxxx, xxxxxxxxx xxxx x technologie přenosů xxxx.

X3.2. Použití xxxxxxxxxx xxxx geneticky xxxxxxxxxxxxxx xxxxx.

X6 STIMULANCIA

ZAKÁZANÉ XXX XXXXXXX

Xxxxxxx xxxxxxxx xxxxx x této xxxxx xxxx Xxxxxxxxxx látky x xxxxxxxx látek xxxxxxxxx x X6.X, xxx xxxx Xxxxxxxxxxxx xxxxx.

Xxxxxxxx xxxxx x xxxx sekci: xxxxxx x xxxxxxxxxxxxxxxxxxxxxxxx (MDMA/„extáze“)

Všechna xxxxxxxxxxx, xxxxxx všech xxxxxxxxx xxxxxxx, např. x- x l-, xxxx zakázána.

Stimulancia xxxxxxxx:

X6.X: XXXXXXXXXXXX STIMULANCIA

•	adrafinil		•	fonturacetam [4-xxxxxxxxxxxxxx (xxxxxxxx)]
•	xxxxxxxxxx		•	xxxxxxxxxx
•	xxxxxxxxx		•	xxxxxxxxxxxxxxx
•	xxxxxxxxxxx		•	xxxxxxxxx
•	xxxxxxxxxx		•	xxxxxxxxxxx
•	xxxxxxxxxx		•	xxxxxxxx
•	xxxxxxxxxxxxxxx		•	xxxxxxxxxxxx(x-)
•	xxxxxxxxx		•	x-xxxxxxxxxxxxxx
•	xxxxxxxxxxx		•	xxxxxxxxx
•	xxxxxx		•	xxxxxxxxxxxxxx
•	xxxxxxxxxxx		•	xxxxxxxxxxxxx
•	xxxxxxxxxx		•	xxxxxxxxx
•	xxxxxxxx		•	xxxxxxxxxx
•	xxxxxxxxx		•	xxxxxxxxx
•	xxxxxxxxxxx
•	xxxxxxxxxxx

Xxxxxxxxx, xxxxx není xxxxxxxx xxxxxx x xxxxx oddíle, je Xxxxxxxxxxx xxxxxx.

X6.X: SPECIFICKÁ XXXXXXXXXXX

Xxxx jiné včetně:

•	2-fenylpropan-1-amin (ß-xxxxxxxxxxxxxx-xxxx, XXXXX)		•	xxxxxxxxxxx		•	xxxxxxxxx
•	3-xxxxxxxxxx-2-xxxx (1,2-xxxxxxxxxxxxxxxxx)		•	xxxxxxxxxxx		•	xxxxxxxxx (xxxxxxxxxxxxx)
•	4-xxxxxxxxxxxxxxxxxx		•	xxxxxxxxxxx		•	xxxxxxx
•	4-xxxxxxxxxx-2-xxxx (1,3-xxxxxxxxxxxxxxx, 1,3 XXXX, xxxxxxxxxxxxxx)		•	xxxxxxxxxx		•	xxxxxxxxxxx
•	4-xxxxxxxxxxxx-2-xxxx (1,3-dimethylbutylamin)		•	hydrafinil (xxxxxxxxx)		•	xxxxxxxxxxx a jeho xxxxxxxx
•	5-xxxxxxxxxx-2-xxxx (1,4-xxxxxxxxxxxxxxx, 1,4-xxxxxxxxxxxxxxxxx, 1,4-XXXX)		•	xxxxxxxxxxxxxxxx (parahydroxyamfetamin)		•	fenmetrazin
•	benzfetamin		•	isomethepten		•	fenprometamin
•	katin1)		•	levmetamfetamin		•	propylhexedrin
•	katinon x xxxx analogy, např. xxxxxxxx, xxxxxxxx a ɑ-xxxxxxxxxxxxxxxxxxxxxx		•	xxxxxxxxxxxx		•	xxxxxxxxxxxxx2)
•	xxxxxxxxxxxxxx (xxxxxxxxxxxxxxxx)		•	xxxxxxxxxxxxxxxxxxxxxxxx		•	xxxxxxxxx
•	xxxxxxx3)		•	xxxxxxxxxxxx3)		•	xxxxxxxxxx
•	xxxxxxxxx (xxxxxxxxx)4)		•	xxxxxxxxxxxxx [(±)-xxxxx-2-(xxxxxxxx-2-xx)-2-(xxxxxxxxx-2- xx)xxxxxx]		•	xxxxxxxxxxxx
•	xxxxxxxx		•	xxxxxxxxxxxx		•	xxxxxxxxx
•	xxxxxxxxxxx		•	xxxxxxxxx		•	xxxxxxxxxxxx (metylendioxyamfetamin)
•	etylamfetamin		•	norfenefrin		•	tuaminoheptan
•	etilefrin		•	oktodrin (1,5-xxxxxxxxxxxxxxxx)

x xxxxx xxxxx x podobnou xxxxxxxxx xxxxxxxxxx nebo xxxxxxxxx xxxxxxxxxxxx účinky

VÝJIMKY

• xxxxxxxx;

• xxxxxxxx xxxxxxxxxxx v xxxxxxx xxxxxx kožního, xxxxxxx, xxxxxx xxxx xxxxxx xxxxxxx (xxxx. xxxxxxxxxx, xxxxxxxxxx, xxxxxxxxxxx, xxxxxxxxxxx, xxxxxxxxx, xxxxxxxxxxxx, xxxxxxxxxx, tramazolin, xylometazolin) x stimulancia xxxxxxxx xx Xxxxxxxxxxxxxx xxxxxxxx 2024⁵⁾.

X7 XXXXXXXXX

XXXXXXXX XXX XXXXXXX

Xxxxxxx xxxxxxxx látky x xxxx xxxxx xxxx Specifické xxxxx.

Xxxxxxxx xxxxx v této xxxxx: xxxxxxxxx (xxxxxx)

Xxxxxxxxxxx xxxxxxxxx, xxxxxx xxxxxx xxxxxxxxxx všech xxxxxxxxx xxxxxxx, např. x- x x, jsou xxxxxxxx.

•	xxxxxxxxxxx		•	xxxxxxxx a jeho xxxxxxxx		•	xxxxxx		•	xxxxxxxxxx
•	xxxxxxxxxxxxx		•	xxxxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxx
•	xxxxxxxxx (heroin)		•	metadon		•	oxykodon		•	tramadol
						•	oxymorfon

S8 XXXXXXXXXXX

XXXXXXXX XXX XXXXXXX

Xxxxxxx zakázané xxxxx x xxxx xxxxx xxxx Xxxxxxxxxx xxxxx. Návykové látky x této xxxxx: xxxxxxxxxxxxxxxxxxx (THC)

Všechny xxxxxxxx x syntetické xxxxxxxxxxx xxxx zakázané, xxxx.

• x xxxxxx (xxxxx, xxxxxxxxx) x konopných xxxxxxxxxx

• přírodní x xxxxxxxxxx xxxxxxxxxxxxxxxxxxxxx (XXX)

• xxxxxxxxxx kanabinoidy xxxxxxxxxxxx xxxxxx XXX

XXXXXXX

• xxxxxxxxxx

X9 XXXXXXXXXXXXXXX

XXXXXXXX PŘI XXXXXXX

Xxxxxxx xxxxxxxx látky x xxxx xxxxx xxxx Xxxxxxxxxx xxxxx.

Xxxxxxx xxxxxxxxxxxxxxx xxxx xxxxxxxx, xxxxx xxxx podávány jakoukoliv xxxxxxxx, xxxxxxxxx [včetně xxxxxxxxxx (xxxx. xxxxxxx, xxxxxxxxxx, xxxxxxxxxxxx)] xxxx xxxxxxxx cestou.

Mimo xxxx xxxxxx:

•	xxxxxxxxxxxx		•	xxxxxxxxxxx		•	xxxxxxxxx
•	xxxxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxxx
•	xxxxxxxxx		•	xxxxxxxxxxxx		•	xxxxxxxxx
•	xxxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxxxx xxxxxxxx
•	xxxxxxxx		•	xxxxxxxxxxxxx
•	xxxxxxxxxxx		•	xxxxxxxxxxxxxxxx

XXXXXXXX

• Xxxx xxxxxxx podání (xxxxxx xxxxxxxxxxx a topického: xxxxxxxx-xxxxxxxxxxxxxx, dermálního, xxxxxxxxxxxxxx, xxxxxxxxxxxxxxxx, xxxxxx x xxxxxxxxxxxx) nejsou xxxxxxxx, xxxxx xx používají x xxxxx výrobcem xxxxxxxxxxxx xxxxx a xxxxxxxxxxxxxx xxxxxxxx.

X1 BETA-BLOKÁTORY

ZAKÁZANÉ X XXXXXXXX XXXXXXXX

Xxxxxxx xxxxxxxx xxxxx v xxxx třídě jsou Xxxxxxxxxx látky.

Beta-blokátory xxxx xxxxxxxx pouze v xxxxxxxxxxxxx xxxxxxxx Při Xxxxxxx x xxx xx xx xxxxxxxx xxxxxxxx (*) x Xxxx soutěž.

• xxxxxxxxxxx (XX)*

• xxxxxxxx/xxxxxxxxxxxx (FIS) – xxxxx xx xxxxxx, akrobatické xxxxx / U-rampa a xxxxxxxxx X-xxxxx / xxx xxx

• xxxxxxxxxxxx xxxxx (XXX)

• xxxxxxxx xxxxxx (CMAS)* v xxxxxxxxxxxx xxxxxxx xxxxxxxx, xxxx harpunou x xxxxxxx xx terč

• xxxxxxxx (xxxxxxx xxxxxxxxxx) (XXXX)

• šipky (WDF)

• xxxx (XXX)

• minigolf (XXX)

• střelba (XXXX, XXX)*

* xxxxxxxx xxxx Xxxx soutěž

Mimo xxxx xxxxxx:

•	xxxxxxxxxx		•	xxxxxxx		•	xxxxxxxxx		•	xxxxxxxxxx
•	xxxxxxxxxx		•	xxxxxxxxx		•	xxxxxxxxxxxx		•	xxxxxxxx
•	xxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxxx
•	xxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxx		•	xxxxxxx
•	xxxxxxxxxx		•	xxxxxxx		•	xxxxxxxxx		•	xxxxxxx

Xxxxxxx x. 2

Xxxxx xxxxxxxxxxx xxxxxxx x xxxxxxxxx xxxxxx
&xxxx;

¹⁾ xxxxx (x-xxxxxxxxxxxxxxxx) x xxxx x-xxxxxx: je xxxxxxxx xxxxx xxx xxxxxxxxxxx x xxxx vyšší xxx 5 mikrogramů x 1 xx.

²⁾ xxxxxxxxxxxxx: xxxxxxxx pouze xxx xxxxxxxxxxx x xxxx xxxxx xxx 150 xxxxxxxxxx x 1 xx.

³⁾ xxxxxxx x metylefedrin: xxxxxxxx xxx xxxxxxxxxxx x xxxx vyšší xxx 10 xxxxxxxxxx x 1 xx.

⁴⁾ epinefrin (xxxxxxxxx): xxxx xxxxxxxx xxxxxxx xxxxxxxx, xxxx. xxxxx, oční, nebo xxxxxxxx xxxxxxxx x xxxxxxxxx xxxxxxxxxx.

⁵⁾ bupropion, xxxxxxxxxx, xxxxxxxxxxxxxxxxx, kofein, xxxxxxx, pipradrol x xxxxxxxx: xxxx xxxxx xxxx zahrnuté xx Xxxxxxxxxxxxxx xxxxxxxx 2024 x xxxxxx považovány xx Xxxxxxxx xxxxx.

Informace

Právní xxxxxxx x. 19/2025 Sb. nabyl xxxxxxxxx xxxx 28.1.2024.

Xxxxx xxxxxxxxxxxx xxxxxxxx xxxxx xxxxxx právních xxxxxxxx x xxxxxxxx xxxx xxxxxxxxxxxxx, xxxxx xx xxxx xxxxxx xxxxxxxxx xxxxx xxxxx xxxxxxxxx xxxxxxxx xxxxxxxx